Journal of Chromatography, 146 (1978) 354-360 Biomedical Applications © Elsevier Scientific Publishing Company, Amsterdam — Printed in The Netherlands CHROMBIO. 189 Note

High-pressure liquid chromatographic determination of cimetidine sulphoxide in human blood and urine

# **R.M. LEE and P.M. OSBORNE**

Department of Biochemistry, Smith Kline & French Laboratories Ltd., Research Institute, Welwyn Garden City, Hertfordshire (Great Britain)

(First received January 10th, 1978; revised manuscript received April 21st, 1978)

Cimetidine [1] an  $H_2$ -antagonist of histamine, has been introduced recently as Tagamet<sup>®</sup> for the treatment of gastric and duodenal ulcers. The major identified metabolite of cimetidine is the sulphoxide [2], which is eliminated from the body mainly by renal excretion. A satisfactory method for the determination of cimetidine in blood and urine has been published [3] and this can now be complemented by a method for the determination of the sulphoxide metabolite in blood and urine using high-pressure liquid chromatography (HPLC) to separate the components of the extract and UV extinction to monitor the column effluent. This method differs in several important respects from that published [3] for the assay of cimetidine itself, but can be used for cimetidine analysis by a simple modification of the solvent system.

## METHODS

# Extraction procedure

All blood samples were heparinized at collection, frozen  $(-20^{\circ})$  as soon as possible thereafter and stored at this temperature until thawed immediately prior to extraction. Urine samples were frozen within 30 min of collection and similarly stored.

The procedure for extraction of cimetidine sulphoxide was the same for blood and urine samples and is only described for blood samples.

A 3-ml sample of the blood to be assayed was made alkaline (pH 9.0) by the addition of 1 ml of N carbonate buffer, which contained a suitable amount (about 2  $\mu$ g) of internal standard (N-cyano-N'methyl-N"-(3-(4-imidazolyl)-propyl)guanidine; compound SK&F 92374)\*. A 4-ml volume of 1-octanol was then added to the samples in 15-ml polythene tubes, which were stoppered and rotated for 15 min on a blood-mixer. After 15 min the octanol layer was

<sup>\*</sup>Available from SK&F Labs., Welwyn Garden City, on request for the analysis of cimetidine sulphoxide.

separated cleanly by centrifugation, removed and stored. A second 4-ml volume of octanol was added and the process repeated, so that the combined octanol extracts (total volume 7 ml) could be re-extracted with 3 ml of 0.02 N HCl by the same rotary mixing and centrifugation technique. After removal of the octanol by aspiration, the acid layer (2.8 ml) was transferred to clean tubes, and 200  $\mu$ l of ethanol added and mixed before saturating the whole with solid potassium carbonate (ca. 5 g). This had the effect of "salting-out" the ethanol into a discrete layer which could be removed after centrifugation and stored at -20° prior to HPLC separation and analysis.

### Chromatography

The following HPLC conditions were employed:Column: LiChrosorb Si 60; 5- $\mu$ m particle size; 25 cm  $\times$  3.2 mm I.D. Solvent: acetonitrile methanol-water (distilled)—ammonium hydroxide (0.88 sp.gr.); (250:20:6:1.5, v/v). Flow-rate: 1 ml/min maintained by a constant flow system (Waters Assoc. 6000). Injection: 10-20  $\mu$ l of the ethanol extract were introduced onto the column via an Altex variable-volume loop injector. Detection: the UV absorption of the column effluent was monitored by a variable wave-length detector (Perkin-Elmer LC55) set at 228 nm. Recording: peaks were recorded on a conventional chart recorder and the areas under them integrated by means of an Infotronics CRS 309 integrator which compensated for baseline drift. Retention: the retention times of compounds of interest were determined by the chart speed of the recorder, and by the programme of the integrator which was reset at the time of each sample injection.

### RESULTS

The relationship between peak height, peak area and the amount of cimetidine sulphoxide applied to the HPLC column is given in Table I; it was found

### TABLE I

### CORRELATION BETWEEN PEAK AREA OR PEAK HEIGHT AND CIMETIDINE SULPH-OXIDE\*

Determined by HPLC-UV analysis. Background peak heights were less than 1 mm, and integrator counts associated with background were not greater than 500. The peak height and area values are the means of four observations, together with their standard deviations.

Concentration of cimetidine sulphoxide in ethanol (mg/l)	Cimetidine sulphoxide in 20-µl injection (ng)	Peak height (mm)		Peak area (relative counts)			
		Range	Mean	Mean		-	•
0.65	13	5-5	5 ± 0	2010 ± 94			
1.30	26	9-11	10 ± 1	3970 ± 198			•
2.60	52	1 <del>9-</del> 21	$21 \pm 1$	8020 ± 301			
5.20	104	38-41	$40 \pm 2$	14940 ± 727			· .
10.40	208	76 <del>-8</del> 3	78 ± 4	29520 ± 356			
20.80	416	158—162	161 ± 2	62400 ± 1496	<b>;</b>	•	

\*Concentrations up to mg/l.

i 1997 - Anna Anglis Fredericas II.	Line and	Lars- Last		lines () figistade.
n na serie de la construction de la La construction de la construction d		e en el sere complete Renerationes	- Ante-Failting	ana kanatoo in
ang kang terupakan pertakan p Pertakan pertakan pert			ion Samero	inited atoms as
				kar soleli selv ne
adite un prag <mark>e</mark> nterador no en esta de Aduar en				ත්ත දේ මහත්ත
	dard Area ratio	18 24 25	1.24 1.26 1.26 1.26 1.26 1.26 1.26 1.26 1.26	s in in this inc
	Internal standard Area Area (rel. count) ratio		ннн нно	eise anterie
	G G	e de la gara Ariege	ා එයේ සොස	issue weeks in the
*	at at	a u <u>nu</u> butu me		rangen (12am -
	Internal sta Area (rel.count)	18535	8 7 7 7 7 7 7	
A£	Area (rel. c	44641 38168 38168 43867 45164 37661	87244 42887 40664	ಗ್ರೆಸ್ ಪ್ರಾಯಾ ನಿಂಗಿ
use de la cal <b>g</b> é cause		40440	2744	en son het sind i
		d 20 de horrais	2,8 N mot62 (4	de preiser dist.
		노벨, 문화 한 영화	see dhe gelaac	
		22 41 22 22	6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
CIMETIDINE SULPHOXIDE EXTRACTION	ine Area (ral. count)	85657 83478 83478 85341 85341 86479 31922	29654 84247 82672 83668 1	n ang ting tengan tengah sa
	le Cri			lete obligation and solution and construction and solution
and held a new 🖁 🖉 a chaire	5 mg/l in Urine Sulphoxide Peak ht. Are (mm)		8	n an an Air Ann an A
ander Sterren ander an 🖉 der Bernarie. Nach der Keiner	6 mg/l ir Sulphox Peak ht. (mm)			n in the second seco
	n n n	109 112 112 115	92 106 106 106 106 7	n o se presidente de la sector d Namenta de la sector
Õ			an a	giali en la companya de la companya
			G	an a
1	1 19 0		<b></b>	n granden en son en
50 20 50 20	Area	5 5 5 5 1 5 5 5 5 1 5 5 5 5 1	5.0 5.3 0.3 0.3	niale i e constante de la const
	da			
ota ji	t ga			· ·
ODUCIBILATY OF CIMETIDINE SULP MPLES onto column 15 µl from a total of 200 µl.	Internal standard Area Ar ral. count) rat	0-0-0		
CI Mo	Interr Area	47719 45417 47148 47148 46334 46126	46732 48092 48092 	ale a statistica de la compo
E OF	S A E	24444 75764	44 48 48 48 48 1	2 (17 - 17 - 17 - 17 - 17 - 17 - 17 - 17
				n an Arthur
	Area Count)		GALES ELEMENTS	
	Area	9261 9261 8706 8822 9821 9821 8662	9294 8206 9270 9270 9270	
MPLES onto co	a Blood Ide Are (rel		686 811	ವರ್ಷ-ಪುರ್ಶನ ಸಂಪರ್ಧದಲ್ಲಿ ಗಳು ಮತ್ತು ಎಂದಿ ಮತ್ತು ಸಂಪರ್ಧದಲ್ಲಿ ಸ
Ö Å Å	n B	na panina seranan Dang karangan diang tina	ana na sana sa mara na sa	and a constraint of the second se
SA BA	PHONE	a salah sa t		
TABLE II TEST OF REPRODUCIBILITY AND URINE SAMPLES Injection Volume onto column 15	1 mg/l in Ble Sulphoxide Peak ht.	800 <b>4</b> 80 8	020 240	n - to allegizations
		565 5 5 6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	28 24 24 24 24 24 26 20 20 20 20 20 20 20 20 20 20 20 20 20	ಲ್ಲಿ ನಿರ್ದೇಶದಿಂದ ಮಾಡಿದ್ದರೆ. ಬೆ.ಎ.ಎ.ಎ.ಕ್.ಕೆ.ಕ್.ಸ್
TABLE II TEST OF AND URI	Sample No. (2 ml)	1.45 C 2.4		
AB ND ND	Sample No. (2 ml)		8 Range Range	وربع سيد بالسجيح
F F A		0.40	SF8 NAG	L LOA
				(法)王 (行)( <i>法</i> )
		read sám read rea	NA ÁS 117 DE	이년(6) 1
가 있다. 1997년 - 1997년 - 1997년 1997년 - 1997년 -	가 가지 가지 않는다. 	あっている ようて 乳子エロー おおい		्र हे है।
	- 3 C. S. & M.	alean (1889) Saithe Carl	487 - ST	년 1911년 - 1912년 - 1912년 1912년 - 1912년 -
a again i a ann i a an		المتوجد والتمك الوارد الدعا	والحادي المتالحية أعاليك	يحتجمو بالبريد الداري

to be linear over the range  $13-416 \text{ ng}/20-\mu \text{l}$  injection, with a minimum reliable estimation of 10 ng. Higher concentrations were not investigated, but the assay was accurate for 200- $\mu$ l ethanol extracts containing 0.1-4.2  $\mu$ g of cimetidine sulphoxide.

The results of extracting known quantities of cimetidine sulphoxide from blood and urine samples are shown in Table II. The standard curve was linear for cimetidine sulphoxide blood concentrations between 0.5 and 5.0 mg/l, and the reproducibility (Table II) at 1 mg/l was excellent (S.D. = 5.6% of





Fig. 1. Injection of a mixture of known quantities of cimetidine, SK&F 92374, creatinine ind, cimetidine, supposide dissolved in ethanol. Solvent system: acetonitrile-methanolvater-0.88g ammonia 250:20:6:1.5, v/v).

ig: 2. Injection of an ethanol extract of a blood sample from a patient receiving cimetidine, sing SK&F 92374 as internal standard. Solvent system: scetonitrile-methanol-water-.88g ammonia 200:30:6:1.5, v/v).



and for a second s and second s






Fig. 4. As Fig. 2, but from a patient receiving cimetidine.

mean for peak area determinations, about 8% of mean for peak height measurement).

For urine, the standard curve was linear between 1 and 8 mg/l. Reproducibility at 5 mg/l was again excellent, with a standard deviation of less than 4% of the mean for peak area estimations. Theoretically, the complete extraction of 2  $\mu$ g of cimetidine sulphoxide from a blood sample would result in a concentration of 10 mg/l in the ethanol available for HPLC. A 15- $\mu$ l injection onto the column would contain 150 ng, giving a peak area of 21,400 counts (Table I). In practice, the count for 8 such samples was an average 8967, giving a recovery of 42%. The recovery from urine was 31% for the extraction of a 2-ml sample containing 10  $\mu$ g of cimetidine sulphoxide. With a minimum reliable determination of 10 ng injected onto the column, the assay is limited to concentrations of cimetidine sulphoxide greater than 0.2  $\mu$ g/ml if 2-ml samples are available for extraction. The analysis of cimetidine sulphoxide in clinical samples is complicated by

the presence of cimetidine itself, and frequently creatinine. The retention times for the HPLC system described herein were 3, 5, 12 and 14 min for

Received the formation of the eres music init unders infrase**e**re . · 唐朝云、宋山西的大学中的人情。 Suggester in andras entres i des sette en formal a s**uf** se à า เหม่งสะเจราประเทศ จะมีของประส์ <mark>ข</mark>องประกับ ไป จำหาด จะมีการสะบาทการ จะมาจักรุส์จะการ สมมัย ใช้สะบาทยอกการปีการสารสะบาที่มีชื่อมีของการปการสู้ก่องไหม่ จะการประกับสารเป็น จะไปประกับ 人名马马克 化拉拉拉 医白色的 inter al second second second second in sing a the store and the sale is 法行任何法法 机合理器 法保证 化试验 1.5 医颈膜炎 医按照子 电输出器 网络马克 and the star that is the 1 na State de la **P**uère pr 4.73. 42.32 <u>ि</u> 

(a) A state is a set of the selection of the set of the set of the set of the set of each in set of the set

A set of a set fitted of the design of the set of th




Fig. 5. Injection of an ethanol extract of a urine sample from a healthy volunteer, who had received cimetidine intravenously 2 h previously. Solvent system as Fig. 1.

cimetidine, internal standard, creatinine and cimetidine sulphoxide respectively (Fig. 1).

The separation of cimetidine from indigenous blood components was not always complete under these conditions, and is better performed using the same solvents in the proportions 200:30:6:1.5 with a flow-rate of 1.5 ml/min (pressure approx. 2500 p.s.i. at the pump). This system gave retention times of approximately 3.0 min for cimetidine and 3.5 min for the internal standard (Fig. 2).

The use of metiamide as internal standard [3] is quite inappropriate under the conditions used for sulphoxide analysis, as solvent systems for clean separation of metiamide [3] gave a long retention time for cimetidine sulphoxide which emerged as a wide-based peak of insufficient height for sensitive assay.

Blood samples taken from patients with renal failure usually contained high creatinine concentrations (Fig. 3). When these same patients were on a regimen of cimetidine (200 mg on three occasions during the day, plus 400 mg at bedtime), the blood samples taken 2—3 h after a 200-mg dose gave chromatograms as in Fig. 4, with peak height and area corresponding to about 0.5 mg/l cimetidine sulphoxide.

For the sequential analysis of cimetidine itself in these samples, it was necessary to allow the creatinine peak to appear before applying the next sample to the column, otherwise the absorption by creatinine at 228 nm seriously distorted the peaks due to cimetidine or internal standard in the following sample.

In blood samples from healthy volunteers or from patients taking cimetidine but free from renal failure, no creatinine or cimetidine sulphoxide has been found, although the lower limit of detection for the latter compound was 0.2 mg/l compared to 0.05 mg/l for cimetidine.

The analysis of cimetidine sulphoxide in urine is illustrated in Fig. 5, where the chromatogram is similar to that obtained from blood except that the cimetidine sulphoxide peak is much more in evidence (corresponding to about 3 mg/l) and was observed in the urine of healthy volunteers after oral administration of cimetidine (200 mg).

Using this technique, it would be possible to detect and quantify cimetidine sulphoxide in blood samples from cases of renal failure, and to follow the output of cimetidine sulphoxide in the urine of healthy volunteers and patients with kidney disease.

#### REFERENCES

- 1 R.W. Brimblecombe, W.A.M. Duncan, G.J. Durant, C.R. Ganellin and M.E. Parsons, J. Int. Med. Res., 3 (1975) 86.
- 2 D.C. Taylor, P.R. Cresswell and D.C. Bartlett, Drug Metab. Disposit., 6 (1978) 21.
- 3 W.C. Randolph, V.L. Osborne, S.S. Walkenstein and A.P. Intoccia, J. Pharm. Sci., 66 (1977) 1148.

and the second provide the second second

Suppose the second second statement of the second s Second s Second s Second s Second se